DSM Capital Partners LLC Increases Position in Abbott Laboratories $ABT

DSM Capital Partners LLC increased its holdings in Abbott Laboratories (NYSE:ABT) by 7.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 832,780 shares of the healthcare product maker’s stock after acquiring an additional 60,432 shares during the period. Abbott Laboratories comprises approximately 1.6% of DSM Capital Partners LLC’s portfolio, making the stock its 20th biggest holding. DSM Capital Partners LLC’s holdings in Abbott Laboratories were worth $111,543,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of ABT. Vanguard Group Inc. increased its position in shares of Abbott Laboratories by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock valued at $23,502,644,000 after purchasing an additional 2,977,715 shares during the last quarter. State Street Corp increased its holdings in Abbott Laboratories by 0.9% during the second quarter. State Street Corp now owns 78,354,270 shares of the healthcare product maker’s stock worth $10,656,964,000 after buying an additional 689,517 shares during the last quarter. Geode Capital Management LLC raised its position in Abbott Laboratories by 3.8% in the second quarter. Geode Capital Management LLC now owns 38,293,067 shares of the healthcare product maker’s stock worth $5,184,589,000 after acquiring an additional 1,390,554 shares during the period. Norges Bank purchased a new position in Abbott Laboratories in the second quarter valued at about $3,026,180,000. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Abbott Laboratories by 0.5% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 13,177,029 shares of the healthcare product maker’s stock valued at $1,792,209,000 after acquiring an additional 68,613 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Ratings Changes

ABT has been the topic of a number of research reports. BTIG Research reaffirmed a “buy” rating and issued a $145.00 price target on shares of Abbott Laboratories in a report on Thursday, November 20th. Mizuho boosted their target price on Abbott Laboratories from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, October 14th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Abbott Laboratories in a research note on Monday, December 29th. Evercore ISI lifted their price objective on Abbott Laboratories from $142.00 to $144.00 and gave the stock an “outperform” rating in a report on Monday. Finally, Wells Fargo & Company upped their price objective on shares of Abbott Laboratories from $142.00 to $146.00 and gave the company an “overweight” rating in a report on Thursday, October 16th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $147.47.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Barclays reaffirmed a constructive view on ABT with a buy/overweight stance and raised its price target, signaling strong analyst confidence that supports further upside. Barclays Sticks to Their Buy Rating for Abbott Laboratories (ABT)
• Positive Sentiment: Barclays also increased its price target from $162 to $169 (overweight), implying meaningful upside from current levels and likely supporting buying interest. Benzinga coverage of Barclays PT raise
• Positive Sentiment: Evercore ISI nudged its target up to $144 and maintained an outperform rating, adding another independent analyst vote of confidence for valuation and growth expectations. Evercore ISI adjusts PT on Abbott Laboratories
• Positive Sentiment: Abbott unveiled Libre Assist, an AI-driven feature in the Libre app aimed at in-the-moment meal guidance for people with diabetes — a product extension that could boost user engagement and CGM stickiness. Product innovation at CES supports the narrative of recurring revenue and device ecosystem strength. Abbott’s new Libre Assist app feature
• Neutral Sentiment: Abbott scheduled its Q4 2025 earnings release and conference call for Jan. 22 (pre-market). This is a key near-term catalyst: results and FY guidance will likely drive the next leg of the stock’s move. Abbott hosts conference call for fourth-quarter earnings
• Neutral Sentiment: Studio coverage and comparisons (Zacks) highlight valuation comparisons with peers like Prestige Consumer Healthcare — useful for value-oriented investors, but not a direct stock driver. PBH vs. ABT: Which Stock Is the Better Value Option?
• Neutral Sentiment: Recent intraday/short-term coverage noting ABT’s outperformance versus the market signals momentum but is not a fundamental change. Abbott (ABT) Rises Higher Than Market: Key Facts

Abbott Laboratories Stock Performance

Shares of ABT opened at $127.91 on Wednesday. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The stock’s 50-day simple moving average is $126.00 and its 200 day simple moving average is $129.51. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70. The stock has a market capitalization of $222.42 billion, a price-to-earnings ratio of 16.03, a price-to-earnings-growth ratio of 2.09 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, meeting the consensus estimate of $1.30. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The firm had revenue of $11.37 billion for the quarter, compared to analysts’ expectations of $11.40 billion. During the same period in the prior year, the business posted $1.21 earnings per share. The company’s revenue was up 6.9% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. Research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend is Thursday, January 15th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s payout ratio is 29.57%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.